Tag Archives: infliximab

Sandoz announces European Commission approval for Zessly® (infliximab) for use in Europe

Posted on 25, May 2018 by

European Commission’s (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable earlier patient access to important medicines and positively impact healthcare systems Zessly is the third EC … Read the full press release →

Posted in European Union, Germany, Healthcare, Pharma & Biotech

Tagged , , , , , ,

Sandoz: EMA Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for marketing authorization of infliximab

Posted on 26, March 2018 by

Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on comprehensive clinical and non-clinical data that is expected to confirm that Sandoz biosimilar infliximab … Read the full press release →

Posted in European Union, Germany, Healthcare, Pharma & Biotech

Tagged , , , , , , , , , ,